Moreover, our data identified low CEA positivity rates in several tumor entities for which high CEA expression levels were suggested in multiple earlier studies, such as, for example, in high-grade serous carcinomas of the ovary [41], or prostatic adenocarcinomas [42]. The gene discussed is CEACAM5; the disease is prostate adenocarcinoma.